Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893451 | 0.93 | MAPT (0.38) | MAPTTDP1THRAFFAR1HTT | |
| SCHEMBL9906491 | 0.89 | THRA (0.39) | MAPTTDP1THRAHTTTHRB | |
| SCHEMBL9906494 | 0.89 | THRA (0.39) | MAPTTDP1THRAHTTTHRB | |
| SCHEMBL12733887 | 0.89 | THRA (0.39) | MAPTTDP1THRAHTTTHRB | |
| SCHEMBL816206 | 0.88 | THRB (0.40) | MAPTAKR1C3HTTCA12CA1 | |
| SCHEMBL823050 | 0.88 | MAPT (0.35) | MAPTAKR1C3TDP1THRAHTT | |
| SCHEMBL9906498 | 0.88 | THRA (0.39) | MAPTTDP1THRAHTTTHRB | |
| SCHEMBL9906496 | 0.88 | THRB (0.38) | MAPTTHRAHTTTHRBPPARA | |
| SCHEMBL12592131 | 0.86 | KMT2A (0.37) | THRAFFAR1HTTTHRB | |
| SCHEMBL15398108 | 0.86 | THRB (0.42) | MAPTTDP1THRBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | H1-4, XPO4, F12 | MAPT 2630/4885AKR1C3 1940/4885TDP1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.